$3.15
2.94%
Nasdaq, Fri, Dec 27 2024
ISIN
US41015N1063
Symbol
HJLI

Hancock Jaffe Laboratories, Inc. Stock price

$3.15
-0.04 1.25% 1M
-2.02 39.07% 6M
-1.99 38.72% YTD
-1.92 37.87% 1Y
-3.54 52.91% 3Y
-8.85 73.75% 5Y
-127.85 97.60% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.09 2.94%
ISIN
US41015N1063
Symbol
HJLI
Sector

Key metrics

Market capitalization $55.24m
Enterprise Value $8.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.17
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-23.41m
Free Cash Flow (TTM) Free Cash Flow $-16.74m
Cash position $48.38m
EPS (TTM) EPS $-1.39
Short interest 8.37%
Show more

Is Hancock Jaffe Laboratories, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Hancock Jaffe Laboratories, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Hancock Jaffe Laboratories, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Hancock Jaffe Laboratories, Inc.:

Buy
100%

Financial data from Hancock Jaffe Laboratories, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.54 0.54
0% 0%
-
-0.54 -0.54
0% 0%
-
- Selling and Administrative Expenses 11 11
3% 3%
-
- Research and Development Expense 12 12
13% 13%
-
-23 -23
8% 8%
-
- Depreciation and Amortization 0.54 0.54
0% 0%
-
EBIT (Operating Income) EBIT -23 -23
8% 8%
-
Net Profit -21 -21
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hancock Jaffe Laboratories, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Head office United States
CEO Robert Berman
Employees 31
Founded 1999
Website www.envveno.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today